Want to see ZBIO full AI Analyst Report?
ZBIO Stock Chart & Stats
$31.65
-$0.60(-1.94%)
At close: 4:00 PM EDT
$31.65
-$0.60(-1.94%)
Day’s Range― - ―
52-Week Range$13.50 - $44.60
Previous CloseN/A
Volume558.98K
Average Volume (3M)662.82K
Market Cap
$1.72B
Enterprise Value$1.35B
Total Cash (Recent Filing)$643.13M
Total Debt (Recent Filing)$389.60M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 18, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.62
Shares Outstanding65,176,720
10 Day Avg. Volume706,076
30 Day Avg. Volume662,819
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue1.35K
Enterprise Value/Gross Profit-22.57
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$44.80Price Target Upside41.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-5.63
Revenue Forecast (FY)$10.22M
Bulls Say, Bears Say
Bulls Say
Improved Equity PositionThe return to positive stockholders’ equity provides a stronger capital foundation than the company had in 2022–2023. This improvement can support continued clinical investment and gives Zenas more balance-sheet capacity, although leverage still limits overall flexibility.
Biologic Immunology Pipeline FocusZenas is focused on biologic therapeutics in immunology and inflammation, areas where successful clinical development could create durable product opportunities. Advancing antibody-based candidates toward commercialization provides a defined long-term business model rather than reliance on unrelated activities.
Annual Revenue Growth In 2025The doubling of annual revenue from 2024 to 2025 indicates that the company had begun expanding reported revenue before the latest trailing period. If sustained alongside clinical progress, this trend could improve operating leverage and provide a broader base for future commercialization.
Bears Say
Minimal Revenue And Severe LossesZenas currently generates very little revenue relative to its cost base and reports a substantial net loss, leaving the business far from breakeven. Persistently weak earnings reduce internal funding capacity and make future performance highly dependent on successful development and commercialization.
Escalating Cash BurnThe increase in operating cash outflows shows that Zenas is consuming cash at a faster rate while funding its operations. Sustained negative operating and free cash flow can pressure liquidity, constrain investment choices, and increase the need for external financing over the coming quarters.
Rising LeverageThe sharp increase in debt has materially reduced financial flexibility despite the company’s return to positive equity. Higher leverage can increase financing obligations and constrain capital allocation, making it more difficult to absorb continued losses or fund the pipeline without additional capital.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $13.50 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.72B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 36 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Aug 13, 2026. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.122 by -$0.648.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.24.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 65,176,720 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.122. Following the earnings report the stock price went down -6.679%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.80 (41.55% Upside)
$44.80 (41.55% Upside)
Blogger Sentiment
Neutral
ZBIO Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 14.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.71%
12-Months-Change
Fundamentals
Return on Equity
-189.68%
Trailing 12-Months
Asset Growth
139.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$44.80
▲(41.55% Upside)
Technical Analysis
Ownership Overview
24.38% Insiders
21.98% Mutual Funds
43.18% Other Institutional Investors
1.71% Public Companies and
Individual Investors